Expert Interview
Discussing the FDA approval of Edwards Lifesciences' Sapien M3 Mitral Valve Replacement System for the treatment of mitral regurgitation
Ticker(s): EWInstitution: UCLA Medical Center
- Interventional cardiologist at UCLA , Medical Director of the Structural Heart Disease Program & Associate Clinical Professor of Medicine at the David Geffen School of Medicine.
- Manages 25 patients with ATTR-CM.
- Areas of expertise include coronary artery disease and structural and valvular heart disease while specializing in complex percutaneous coronary interventions including the use of rotational atherectomy.
How many patients with symptomatic mitral regurgitation do you manage each month who are currently considered unsuitable for surgery or edge-to-edge repair?
Added By: dami_adminWhat are your expectations or concerns regarding longer-term outcomes, durability, and evidence generation for this transseptal TMVR approach, beyond the one-year ENCIRCLE data?
Added By: dami_adminOn a scale from 1 to 10, how excited are you about the clinical impact of the newly approved SAPIEN M3 system in your practice?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
